Marketometer

Short

Trend Resistance

Uptrend Above: 25030

Bull Market Above: 25210

Term

Mid Point Acts

Mid Point: 25200

Mid Range: 24680 - 25200

View

Trend Suport

Down Trend Below: 24420

Bear Market Below: 24290

Short Term View Historic Data

Nifty View On: Monday 20 Oct 2025

Day Close 25709	Day High 25781	Day Low 25508	Day Avg 25666	17 Oct 2025	5 SMA 25398	20 SMA 25098	50 SMA 24929	100 SMA 24986	200 SMA 24230
Dhas 0.25	Macs 17.25	Dwad 0.01	Mpas 0	Monday View	Resist 2 26070	Resist 1 25980	Mid Point 25730	Suport 1 25470	Suport 2 25400
52W High 25781	52w Low 21743	52w Down 0.28%	52w Up 18.24%	Week View	Resist 2 26410	Resist 1 26230	Mid Point 25730	Suport 1 25210	Suport 2 25080
5d High 25781	5d Low 25060	10d High 25781	10d Low 24881	Days High & Low	20d High 25781	20d Low 24587	50d High 25781	50d Low 24337	All Avg 25249

Daily And Weekly Historic Prediction Data

Nifty Last Five Days Moves

SNo.	Date	Day Close	Day High	Day Low	20 DMA	50 DMA	200 DMA	All Avg
1	17 Oct 2025	25709	25781	25508	25098	24929	24230	25209
2	16 Oct 2025	25585	25625	25376	25084	24908	24220	25133
3	15 Oct 2025	25323	25365	25159	25071	24891	24211	25003
4	14 Oct 2025	25145	25310	25060	25067	24876	24203	24944
5	13 Oct 2025	25227	25267	25152	25063	24868	24196	24962

Nifty Historic Data And Moving Avg

Go Back

Akums Drugs and Pharmaceuticals Limited Pursuant to Regulation 30 of SEBI (Listing Obligations a...

Posted: 24 Dec 2024

Akums Drugs and Pharmaceuticals Limited Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (SEBI Regulation) we would like to inform you that Akums Drugs and Pharmaceuticals Limited (hereinafter referred to as “Akums”) has entered into an agreement with one of Leading Global Pharma Company (“Company”) for Manufacture and Supply of selected pharmaceutical formulations in European Market. Akums group will manufacture and supply multiple SKUs of Oral Liquid Formulation to be marketed in multiple European countries by the Company. This is in line with Akums growth objective of expanding in European and other regulated markets. The commercial supply of these products from Akums will commence in 2027 till 2032. Akums group will also initiate European approvals of its oral liquid site which it intends to leverage to manufacture these products. The approval of the site and the product dossiers is expected to be received by 2026. Akums already has 2 of its sites (Injectable and Oral Solids) approved by European Regulators. The composite value of the agreement is approx. Euro 200 million (INR 1,760 crores approx). Akums group, against this agreement, will receive an upfront payment for product development and site approval from European authorities. The project has been secured with an upfront payment of Euro 100 million (INR 880 crores). Speaking on this development, Mr. Sanjeev Jain, Managing Director of Akums added “It gives us immense pleasure to enter in a strategic collaboration to manufacture and supply a globally renowned brand for one of the largest multinational pharma company. This opens doors for us to further expand our footprints in regulated markets and replicate the domestic CDMO success globally.” Mr. Sandeep Jain, Managing Director of Akums added “These products are currently being manufactured in Europe. Manufacturing these products in India opens further collaboration opportunities with other global pharma companies to optimize their manufacturing costs and make their supply chain robust. This association is the testimony of our manufacturing excellence and our world class R&D capabilities. With this, we will add one more dosage form in our portfolio, can be offered in European market. Akums already has European approved facility for tablets, hard gelatin capsules, sachets, ampoules, vials, eye-drops and dry powder injection.” Other details required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with the SEBI Circular No. SEBI/HO/CFD/CFDPoD1/P/CIR/2023/123 dated 13th July 2023 are provided herein as Annexure-A.

"In investing, what is comfortable is rarely profitable." — Robert Arnott

Be prepared to invest in a down market and to "get out" in a soaring market, as per the philosophy of Warren Buffett.

Date	Macs	Dcmp
17/10 2025	8.45	-18
16/10 2025	-1.72	-39
15/10 2025	-4.28	-53
14/10 2025	-3.77	-47
13/10 2025	-2.90	-43
10/10 2025	-9.51	-50
09/10 2025	-7.03	-62
08/10 2025	-7.37	-56
07/10 2025	1.58	-57
06/10 2025	0.45	12
03/10 2025	3.55	63
01/10 2025	1.07	-25
30/09 2025	6.41	37
29/09 2025	10.43	-8
26/09 2025	8.74	80
25/09 2025	11.46	13
24/09 2025	7.01	81

User Register

User Login

You Are Not Admin

Nifty: 25709 (124)